STOCKHOLM, Sweden, 5th December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall have four members, in accordance with the applicable instructions resolved by the Annual General Meeting 2020. The three largest shareholders who are registered with Euroclear Sweden AB on the last of September before […]
STOCKHOLM, den 5 december 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) presenterar idag enligt den gällande instruktionen (beslutad av årsstämman 2020) sin valberedning som ska som bestå av fyra ledamöter. De tre största aktieägarna som är registrerade hos Euroclear Sweden AB den sista september innan stämman ska kontaktas av bolagets styrelseordförande. […]
STOCKHOLM, den 30 november 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att man byter Certified Adviser från Erik Penser Bank AB till Carnegie Investment Bank AB (publ). Lipidor har ingått avtal med Carnegie Investment Bank AB (publ) avseende tjänsten som Certified Adviser. Carnegie Investment Bank AB (publ) tillträder som […]
STOCKHOLM, Sweden, 30th November 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Lipidor has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB […]
STOCKHOLM, Sweden, 27th October 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that the company has filed a new patent application with the European Patent Office (EPO). The patent originates from the development that took place during the reformulation work with AKP02, now AKP02G2. In line with Lipidor's strategy, the […]
STOCKHOLM den 27 oktober 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att bolaget har lämnat in en ny patentansökan till den europeiska patentmyndigheten (European Patent Office, EPO). Patentet är sprunget ur den utveckling som skett under omformuleringsarbetet med AKP02, numera AKP02G2. I linje med Lipidors strategi ser bolaget kontinuerligt […]
STOCKHOLM, Sweden, 18th October 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that a new agreement has been reached with RELIFE S.r.l. regarding the company's psoriasis project. The new terms relate to geographic expansion through the addition of the Asia-Pacific region and an updated timeline. Lipidor has previously signed a […]
STOCKHOLM, Sverige, 18 oktober 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att en ny överenskommelse träffats med RELIFE S.r.l. avseende bolagets psoriasisprojekt. De nya villkoren avser geografisk expansion genom tillägg av Asia-Pacific regionen samt en uppdaterad tidslinje. Lipidor har sedan tidigare tecknat ett licensavtal i vilket Lipidor ger RELIFE […]
STOCKHOLM, Sweden, 20th September 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) has signed an agreement with Cliantha Research to conduct a phase III study with the drug candidate AKP02G2, for the treatment of psoriasis. The study is expected to begin recruitment of patients in the first half of 2024 and Lipidor […]
STOCKHOLM, den 20 september 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) har tecknat ett avtal med Cliantha Research för genomförande av en fas III studie med läkemedelskandidaten AKP02G2, för behandling av psoriasis. Studien förväntas påbörja rekrytering av patienter under det första halvåret 2024 och vi hoppas kunna presentera studieresultat redan i […]